BR0112429A - Moduladores de receptor de quimiocina, preparação e uso destes moduladores - Google Patents

Moduladores de receptor de quimiocina, preparação e uso destes moduladores

Info

Publication number
BR0112429A
BR0112429A BR0112429-3A BR0112429A BR0112429A BR 0112429 A BR0112429 A BR 0112429A BR 0112429 A BR0112429 A BR 0112429A BR 0112429 A BR0112429 A BR 0112429A
Authority
BR
Brazil
Prior art keywords
modulators
chemokine receptor
terminus
treatment
terminal
Prior art date
Application number
BR0112429-3A
Other languages
English (en)
Inventor
Robin Offord
Hubert Gaertner
Oliver Hartley
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Publication of BR0112429A publication Critical patent/BR0112429A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MODULADORES DE RECEPTOR DE QUIMIOCINA, PREPARAçãO E USO DESTES MODULADORES". São revelados moduladores de receptor de quimiocina compreendendo uma terminação carboxil (terminação C) e/ou uma terminação amino (terminação N) quimicamente modificadas para modular a potência e propriedades farmacocinéticas, bem como métodos de produção e uso. Os compostos e métodos da invenção são exemplificados por novos análogos N-terminais, C-terminais e N/C-terminais de quimiocinas CC e CXC. Os análogos de modulador de receptor de quimiocina da invenção são úteis no tratamento de distúrbios envolvendo a quimiocina de ocorrência natural que os análogos da invenção antagonizam, como por exemplo, para o tratamento de distúrbios relacionados ao HIV e à AIDS e para o tratamento da asma, rinite alérgica, dermatite atópica, ateroma/aterosclerose, rejeição de transplante de órgão e artrite reumatóide.
BR0112429-3A 2000-07-12 2001-07-12 Moduladores de receptor de quimiocina, preparação e uso destes moduladores BR0112429A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21768300P 2000-07-12 2000-07-12
PCT/US2001/021934 WO2002004499A1 (en) 2000-07-12 2001-07-12 Chemokine receptor modulators, production and use

Publications (1)

Publication Number Publication Date
BR0112429A true BR0112429A (pt) 2003-12-30

Family

ID=22812056

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0112429-3A BR0112429A (pt) 2000-07-12 2001-07-12 Moduladores de receptor de quimiocina, preparação e uso destes moduladores
BR0112428-5A BR0112428A (pt) 2000-07-12 2001-07-12 Quimiocinas sintéticas boativas modificadas por polìmero e métodos para sua produção e uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0112428-5A BR0112428A (pt) 2000-07-12 2001-07-12 Quimiocinas sintéticas boativas modificadas por polìmero e métodos para sua produção e uso

Country Status (14)

Country Link
US (1) US20050089970A1 (pt)
EP (2) EP1307216A4 (pt)
JP (3) JP2004502783A (pt)
KR (2) KR20030032977A (pt)
CN (2) CN1441808A (pt)
AU (2) AU2002218769A1 (pt)
BR (2) BR0112429A (pt)
CA (2) CA2412150A1 (pt)
IL (2) IL153785A0 (pt)
MX (2) MXPA03000311A (pt)
NO (2) NO20030110L (pt)
RU (1) RU2003104024A (pt)
WO (2) WO2002004499A1 (pt)
ZA (2) ZA200300313B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482425B2 (en) 1999-08-26 2009-01-27 Amylin Pharmaceuticals, Inc. Compositions for lipid matrix-assisted chemical ligation
AU2001273388B2 (en) 2000-09-08 2005-01-13 Gryphon Therapeutics, Inc. "Pseudo"-native chemical ligation
DK1515990T3 (da) 2002-06-12 2007-06-11 Applied Research Systems Antagonister af CXCR3-bindende CXC chemokiner
WO2004017999A1 (en) * 2002-08-16 2004-03-04 University Of Bern Non-glycosylated polyacrylamide conjugates and their use for cytoprotection
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7482427B2 (en) 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
JP2007501811A (ja) * 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
CA2561171A1 (en) * 2004-03-30 2005-10-20 Amylin Pharmaceuticals, Inc. Synthetic chemokines, methods of manufacture, and uses
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
CN100467487C (zh) 2004-12-14 2009-03-11 北京大学 具有多种功能的多肽
WO2006069449A1 (en) * 2004-12-29 2006-07-06 The University Of British Columbia Chemokine receptor-independent immunomodulatory and anti-proliferative activity
AU2006313464B2 (en) * 2005-11-11 2012-07-12 Proteogen Bio S.R.L. Method of converting water-soluble active proteins into hydrophobic active proteins, the use of the same for the preparation of monomolecular layers of oriented active proteins, and devices comprising the same
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
US10741034B2 (en) * 2006-05-19 2020-08-11 Apdn (B.V.I.) Inc. Security system and method of marking an inventory item and/or person in the vicinity
CA2692240C (en) 2006-06-22 2018-03-13 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
JP2010514422A (ja) * 2006-12-22 2010-05-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新規ｔａａ変種に基づく新たな融合分子
TWI405779B (zh) * 2007-08-01 2013-08-21 私立中原大學 兩性高分子及其形成方法與應用
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US20130053257A1 (en) * 2010-02-08 2013-02-28 Paul E. Oran RANTES Multiplexed Assay, RANTES Variants Related to Disease, and RANTES Variants Related to Enzymatice Activity
LT2867251T (lt) * 2012-06-29 2019-11-25 Bristol Myers Squibb Co Glikoproteinų agregacijos sumažinimo būdai
US10995371B2 (en) 2016-10-13 2021-05-04 Apdn (B.V.I.) Inc. Composition and method of DNA marking elastomeric material
US10920274B2 (en) 2017-02-21 2021-02-16 Apdn (B.V.I.) Inc. Nucleic acid coated submicron particles for authentication
CN110892990B (zh) * 2019-10-11 2023-03-31 内蒙古伊利实业集团股份有限公司 益生菌益生元食用组合物及其应用
CN112129946A (zh) * 2020-08-16 2020-12-25 陆修委 无糖链型惰性蛋白封闭剂的制备方法及应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3815826A1 (de) * 1988-05-09 1989-11-23 Henkel Kgaa Verfahren zur herstellung von vicinal diacyloxysubstituierten verbindungen
US5470829A (en) * 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JPH04503607A (ja) * 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5275838A (en) * 1990-02-28 1994-01-04 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5434192A (en) * 1990-09-19 1995-07-18 Atlantic Richfield Company High-stability foams for long-term suppression of hydrocarbon vapors
FR2672053B1 (fr) * 1991-01-30 1993-04-23 Atochem Polyether bloc amides, leur procede de synthese.
FR2673946B1 (fr) * 1991-03-15 1993-05-28 Atochem Polyether bloc amides, leur procede de synthese.
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
CA2129442C (en) * 1992-02-13 2003-05-27 Morten P. Meldal Polyethylene or polypropylene glycol containing polymer
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5589356A (en) * 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
AU2826495A (en) * 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5646285A (en) * 1995-06-07 1997-07-08 Zymogenetics, Inc. Combinatorial non-peptide libraries
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5919442A (en) * 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
ES2420106T3 (es) * 1995-12-18 2013-08-22 Angiodevice International Gmbh Composiciones de polímeros reticulados y métodos para su uso
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
KR20000029673A (ko) * 1996-08-02 2000-05-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 단일의공유결합된ｎ-말단수용성폴리머를갖는폴리펩티드
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6214540B1 (en) * 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
AU750244B2 (en) * 1997-09-04 2002-07-11 Gryphon Sciences Modular protein libraries and methods of preparation
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US6111107A (en) * 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
DK1098664T3 (da) * 1998-07-22 2003-11-17 Osprey Pharmaceuticals Ltd Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser
AU2001273388B2 (en) * 2000-09-08 2005-01-13 Gryphon Therapeutics, Inc. "Pseudo"-native chemical ligation

Also Published As

Publication number Publication date
US20050089970A1 (en) 2005-04-28
RU2003104024A (ru) 2004-06-27
CA2412150A1 (en) 2002-01-17
KR20030032977A (ko) 2003-04-26
ZA200300312B (en) 2004-02-04
IL153789A0 (en) 2003-07-31
EP1299415A4 (en) 2005-01-19
IL153785A0 (en) 2003-07-31
CN1460023A (zh) 2003-12-03
JP2007302667A (ja) 2007-11-22
NO20030111D0 (no) 2003-01-09
AU2002218769A1 (en) 2002-01-21
ZA200300313B (en) 2004-02-04
NO20030110L (no) 2003-03-12
CA2412162A1 (en) 2002-01-17
NO20030111L (no) 2003-03-12
JP2004517040A (ja) 2004-06-10
KR20030036591A (ko) 2003-05-09
WO2002004499A1 (en) 2002-01-17
AU2001273387A1 (en) 2002-01-21
EP1307216A1 (en) 2003-05-07
JP2004502783A (ja) 2004-01-29
EP1307216A4 (en) 2005-01-12
MXPA03000310A (es) 2004-12-13
MXPA03000311A (es) 2004-12-13
WO2002004015A9 (en) 2003-08-07
CN1441808A (zh) 2003-09-10
NO20030110D0 (no) 2003-01-09
EP1299415A1 (en) 2003-04-09
BR0112428A (pt) 2003-11-25
WO2002004015A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
BR0112429A (pt) Moduladores de receptor de quimiocina, preparação e uso destes moduladores
JP4478714B2 (ja) イガイ接着蛋白質
BR9406232A (pt) Novo agente para controle da atividade celular
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
ES2118820T3 (es) Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.
BR0315327A (pt) Antagonistas de il-15
DE60205564D1 (de) N-Adamantylalkyl Benzamide Derivativen als p2x7-rezeptor antagonisten
DE602004023725D1 (de) Muteine von tränen-lipocalin
DK0730587T3 (da) 3-phenyl-2-isoxazoliner som anti-inflammatoriske midler
ES2141761T3 (es) Secuencias de dna codificantes de nuevos factores de crecimiento/diferenciacion.
WO2006083301A3 (en) Immunogenic compositions comprising hmgb1 polypeptides
DK1179014T3 (da) Derivater af Z-domænet fra staphylococcalt protein A (SPA), som interagerer med mindst ét domæne fra human faktor VIII
WO2006069331A3 (en) Compositions and methods for producing recombinant proteins
BRPI0416807A (pt) sistemas de expressão aperfeiçoados com secreção de sistema sec
ES2192561T3 (es) Adn que codifica el receptor ip de prostaglandina.
ATE170532T1 (de) Prostaglandin rezeptor fp und kodierende dns
BR9911349A (pt) Genes para a biossìntese de epotilonas
AU8840401A (en) Plant polynucleotides encoding novel Na<sup>+</sup>/H<sup>+</sup> antiporters
YU394A (sh) Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu
HUP0003563A2 (hu) Aminoterminálisa felől csonkolt MCP-2 mint kemokinantagonista
MXPA03010158A (es) Sulfonamidas.
WO2003004525A3 (en) Isolation and purification of plasmodium falciparum merozoite protein-142
BR9812773A (pt) "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
YU13392A (sh) ANTITELA NA HUMANI RECEPTOR ZA IgE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,6A E 7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.